AKT1 and neuroblastoma: However, while the HER1-specific tyrosine kinase inhibitor ZD1839 (Iressa, gefitinib) markedly reduces receptor activation and PI3K/AKT signaling, it is not effective on MAPK in neuroblastoma [20].